US Stock MarketDetailed Quotes

ENLV Enlivex Therapeutics

Watchlist
  • 1.260
  • +0.010+0.80%
Close Dec 11 16:00 ET
  • 1.280
  • +0.020+1.59%
Pre 08:50 ET
27.71MMarket Cap-1.29P/E (TTM)

About Enlivex Therapeutics Company

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Company Profile

SymbolENLV
Company NameEnlivex Therapeutics
Listing DateJul 31, 2014
Issue Price11.00
Founded2012
CEOMr. Oren Hershkovitz, PhD
MarketNASDAQ
Employees49
Fiscal Year Ends12-31
Address14 Einstein Street
CityNess Ziona
ProvinceTel Aviv
CountryIsrael
Zip Code7403618
Phone972-8-662-3301

Company Executives

  • Name
  • Position
  • Salary
  • Oren Hershkovitz, PhD
  • Chief Executive Officer
  • --
  • Shachar Shlosberger, C.P.A.
  • Chief Financial Officer
  • --
  • Dr. Roger J. Pomerantz, F.A.C.P.,M.D.
  • Vice Chairman of the Board
  • --
  • Shai Novik, M.B.A.
  • Executive Chairman of the Board
  • --
  • Dr. Brian Schwartz, M.D.
  • Director
  • --
  • Dr. Gili Hart, PhD
  • Independent Director
  • --
  • Dr. Abraham Havron, PhD
  • Independent Director
  • --
  • Andrew E. Singer
  • Independent Director
  • --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.